The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
Alpelisib/Fulvestrant combo improves OS, PFS for patients with previously-treated PIK3CA-Mutated, HR+, HER2− advanced breast cancer ...
Proteinuria (protein in urine) is common with complement 3 glomeropathy and is a strong predictor of disease progression and end-stage kidney failure.
Stress, the body's natural response to different types of challenges and daily problems, is an inherently harmless state ...
US FDA grants fast track designation to Complement Therapeutics’ gene therapy candidate CTx001 to treat geographic atrophy: Munich Saturday, January 10, 2026, 17:00 Hrs [IST] Co ...
The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback